[Shanghai, October 26, 2025] — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, and Hillhouse Investment Management (“Hillhouse”), one of the world’s leading global private alternative asset managers, announced that they have reached an agreement for Hillhouse to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO).

Strategically divesting the clinical research services business allows WuXi AppTec to further invest in and strengthen its core Contract Research, Development, and Manufacturing Organization (CRDMO) platform. This builds on the company’s legacy of exceptional drug discovery, laboratory testing, process development and manufacturing services.

“We are confident that Hillhouse’s expertise and teams will enable these businesses to reach new heights and deliver continued excellence in clinical research and site management,” said Steve Yang, Co-CEO of WuXi AppTec. “This transaction is also an important step in WuXi AppTec’s efforts to sharpen our focus on our core CRDMO strategy. Powered by our unique CRDMO platform, we are accelerating the expansion of our global capabilities and capacities to better serve our customers for the benefit of patients worldwide.”

WuXi AppTec signed a definitive agreement with Hillhouse on October 24, 2025. The transaction is subject to all mandatory government approvals/filings by all parties.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

About Hillhouse

Founded in 2005, Hillhouse Investment (“Hillhouse”) is a global alternative investment manager dedicated to partnering with high quality businesses for the long-term. With over two decades of experience, Hillhouse has grown to be among the largest alternative asset managers with a range of investment strategies that span public equities, private equity (across buyout, venture capital and growth strategies), private credit and real assets. 

Hillhouse collaborates with industry-defining enterprises, aiming to establish alignment with sustainable, forward-thinking companies across healthcare, business services, consumer, and industrial sectors. The firm manages capital on behalf of leading institutional clients worldwide, including university endowments, foundations, and sovereign wealth funds across the Americas, Europe, Asia and the Middle East. 

For more information, visit www.hillhouseinvestment.com